Has seen its share price rocket following news of positive results with its pre-clinical in-vivo study into breast cancer.
The Oxford-headquartered venture declared that the positive results provide further validation as to the predictive capability of the company's technology.' The study involved a 'virtual tumour' model in which the company designed 'innovative combination regimes' for the anti-cancer drugs docetaxel and gemcitabine. Three new schedules were tested in a breast cancer pre-clinical in-vivo model and Physiomics enthused that their 'predictions were substantiated'.
The best schedule showed a 74 per cent inhibition in tumour growth compared to the untreated control group, which was 50 per cent more efficient than the original schedule. Physiomics add that the greater efficacy was achieved 'without increasing the toxicity.'
CEO Mark Chadwick enthused that the group was 'pleased with the results of this study' adding that 'we believe that the optimal clinical scheduling for these drugs is still an open question' and that 'our rational approaches could help to resolve it.
Onwards and upwards from here as investors await further news
strong buy
No comments:
Post a Comment